NEW YORK (GenomeWeb News) — Bruker BioSciences today said it expects to pocket at least $14.7 million after issuing a stock offering.
The company said proceeds from the sale may be used for general purposes, repaying debts, and potential acquisitions. 
The company said it expects to sell 10.4 million shares at $7.10 apiece. Bruker said it expects selling stockholders to earn roughly $54.9 million. 

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.